Desidustat VS Darbepoetin in anemia of chronic kidney disease patients undergoing maintenance haemodialysis

Not yet recruiting

• Conditions: Chronic kidney disease, stage 5,

• Registration Number: CTRI/2023/07/054621
• Lead Sponsor: Kalinga institute of medical sciences

Brief Summary

Erythropoiesis stimulating agents are currently the mainstay of treatment of anemia in chronic kidney disease .New approach in treatment of anemia in chronic kidney disease  patients is the use of agents that stimulate endogenous erythropoietin production.Desidustat(Prolylhydroxylase inhibitor ) stimulate endogenous erythropoietin production.

Primary objective:To  determine the effectiveness of prolyl hydroxylase inhibitor(Desidustat) in increasing haemoglobin levels in patients with anemia of chronic kidney disease undergoing maintenance haemodialysis.

Secondary objective:1.Comparing efficacy with darbepoetin

2.Comparision of safety with that of darbepoetin.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-09-21
• Study Start: 2023-12-07

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Maintenance Haemodialysis Patients with Hb8-11 g/dl in chronic kidney disease.

Exclusion Criteria

• Patient with iron deficiency anemia .
• History of Bleeding disorders.
• Red blood cell transfusion within 8 weeks prior to enrollment.
• History of previous or concurrent cancer.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of patients reaching target haemoglobin(Hb g/dl) who are receiving desidustat.	follow up at 4weeks 8weeks | & 12weeks

Secondary Outcome Measures

Name	Time	Method
Saftey of desidustat.

Trial Locations

Locations (1)

Kalinga institute of medical sciences; 🇮🇳 Khordha, ORISSA, India

Kalinga institute of medical sciences

🇮🇳Khordha, ORISSA, India

Dr Challagulla Madhu Babu

Principal investigator

9553084064

madhubabuchallagulla@gmail.com